Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Technology appraisal guidance
Reference number: TA258
Published: 27 June 2012

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
10 May 2012
(356.71 Kb 43 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 May 2012